新型冠状病毒肺炎治疗药物的最新研发进展

An Update on Research Progress of Therapeutic Agents for COVID-19

2019新型冠状病毒(SARS-CoV-2)感染已造成全球性严重疫情,目前有超600万人死亡。尽管世界各国已经开展大范围疫苗接种,但随着病毒不断变异进化,SARS-CoV-2感染率依旧居高不下,其治疗药物的研发迫在眉睫。近期Paxlovid及bebtelovimab两款新药成功获批上市,中美两国的新型冠状病毒肺炎诊疗指南也相应更新了治疗推荐。该文聚焦于两国新型冠状病毒肺炎诊疗指南的药物推荐,将目光锁定在近期获批的4款药物Paxlovid、莫那匹韦、bebtelovimab和安巴韦单抗/罗米司韦单抗注射液,梳理总结其作用机制、研发进程及临床疗效的最新研究,并综合其作用特点及临床使用进行阐述和讨论,为未来抗新型冠状病毒药物的临床使用和进一步研发提供思路。

The SARS-CoV-2 infection has caused a serious public health threat globally with over 6 million deaths reported.Despite large-scale vaccination around the world,the infection rate remains high due to rapid mutations of the coronavirus,which warrants the development of novel therapeutic agents for the treatment of COVID-19.Treatment guidelines in both China and the U.S.have been updated on their recommendations regarding the recent authorizations of Paxlovid and bebtelovimab.This paper focuses on the four newly authorized agents,Paxlovid,molnupiravir,bebtelovimab,and amubarvimab/romlusevimab,for a review of their mechanisms,development progress,and clinical evidence.The characteristics and comparative use of the above agents are discussed to provide perspectives for current practice and future development.